Entera Bio Reports $5.2 Million Net Loss in Q2 2025, Revenue Declines to $42,000

Entera Bio Ltd. reported its financial results for the second quarter of 2025, revealing a net loss of $5.2 million for the six months ended June 30, 2025, compared to a net loss of $4.2 million for the same period in 2024. The company generated $42,000 in revenue during the first half of 2025, a decrease from $57,000 in the prior year, primarily due to the completion of a research services agreement. Operating expenses increased to $5.2 million from $4.2 million year-over-year, driven by higher research and development costs, which rose to $2.6 million from $1.8 million, reflecting ongoing clinical development activities.

The company’s total assets as of June 30, 2025, amounted to $19.7 million, up from $9.4 million at the end of 2024. This increase was largely attributed to cash and cash equivalents, which rose to $10.9 million from $8.7 million, bolstered by financing activities including the issuance of ordinary shares under an at-the-market (ATM) program and a collaboration agreement with OPKO Health, which provided $8 million in funding. Entera's accumulated deficit reached $119.2 million as of June 30, 2025, indicating the ongoing financial challenges faced by the company as it continues to invest heavily in research and development.

Strategically, Entera Bio has made significant advancements in its product pipeline, particularly with its lead candidate, EB613, an oral treatment for osteoporosis. The company is preparing to initiate a Phase 3 registrational study for EB613, following positive feedback from the FDA regarding its clinical development plan. Additionally, Entera is collaborating with OPKO on the development of an oral GLP-1/glucagon dual agonist, which is expected to address obesity and metabolic disorders. The collaboration agreement with OPKO not only enhances Entera's product offerings but also provides essential funding for ongoing research.

Operationally, Entera Bio has maintained a workforce of 21 employees, all based in Israel, and continues to focus on expanding its clinical trials and product development efforts. The company has emphasized its commitment to advancing its N-Tab™ technology platform, which aims to facilitate the oral delivery of peptide therapies. Despite the geopolitical tensions in the region, Entera has reported that its operations have remained largely unaffected, and it continues to monitor the situation closely.

Looking ahead, Entera Bio anticipates that its existing cash resources will be sufficient to support operations through the middle of the third quarter of 2026. However, the company acknowledges the need for additional funding to commence the Phase 3 program for EB613 and to sustain its ongoing research initiatives. Entera is exploring various financing options, including public and private equity offerings, to secure the necessary capital for its future endeavors.